Cases & Deals

  • Home
  • Practices
  • Elaia Partners leads €4 million financing round of Mablink Bioscience

Share

Elaia Partners leads €4 million financing round of Mablink Bioscience

April 2021

Client(s) Elaia Partners

Jones Day represented Elaia Partners in connection with the €4 million seed round of financing of Mablink Bioscience, a company developing the next generation of antibody-drug conjugates (ADC) through its proprietary hydrophilic drug-linker PSARlink™ platform.

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.